These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26825470)

  • 1. Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia.
    Patel AA; Budoff MJ
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):145-9. PubMed ID: 26825470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
    Backes J; Anzalone D; Hilleman D; Catini J
    Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
    Singh S; Arora RR; Singh M; Khosla S
    Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.
    Zambon A; Pirillo A; Zambon S; Norata GD; Catapano AL
    Curr Atheroscler Rep; 2020 Oct; 22(12):74. PubMed ID: 33009961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
    Scherer DJ; Nicholls SJ
    Vasc Health Risk Manag; 2015; 11():203-9. PubMed ID: 25848301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study.
    Tatsuno I; Kudou K; Kagawa T
    Cardiovasc Ther; 2015 Dec; 33(6):317-23. PubMed ID: 26222126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
    Mason RP; Libby P; Bhatt DL
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1135-1147. PubMed ID: 32212849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
    Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M
    Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
    Fialkow J
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.
    Peters BS; Wierzbicki AS; Moyle G; Nair D; Brockmeyer N
    Clin Ther; 2012 Jan; 34(1):67-76. PubMed ID: 22212377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
    Weintraub HS
    Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
    Harris WS; Dayspring TD; Moran TJ
    Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
    Weintraub H
    Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
    Preston Mason R
    Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
    Nelson JR; True WS; Le V; Mason RP
    Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.
    Tatsuno I; Saito Y; Kudou K; Ootake J
    J Clin Lipidol; 2013; 7(6):615-25. PubMed ID: 24314359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids.
    Toth PP; Dayspring TD; Pokrywka GS
    Curr Atheroscler Rep; 2009 Jan; 11(1):71-9. PubMed ID: 19080732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Icosapent ethyl for the treatment of hypertriglyceridemia.
    Ballantyne CM; Braeckman RA; Soni PN
    Expert Opin Pharmacother; 2013 Jul; 14(10):1409-16. PubMed ID: 23701295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. History and future of omega-3 fatty acids in cardiovascular disease.
    Sperling LS; Nelson JR
    Curr Med Res Opin; 2016; 32(2):301-11. PubMed ID: 26566071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.